LOGIN  |  REGISTER
Compass Therapeutics

BIMI Announces Results of 2023 Annual General Meeting of Stockholders

January 03, 2024 | Last Trade: US$ 0 0.00 0.00

New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company’s 2022 Annual General Meeting of Stockholders (the “Annual Meeting”) held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022.

At the Annual General Meeting the shareholders voted and approved;

1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and qualified;

2. The adoption of an amendment to the Company’s Amended and Restated Bylaws to change the Company’s staggered board (also known as classified board) to a standard board composition;

3. The adoption of an amendment to the Company’s Amended and Restated Certificate of Incorporation to change the Company’s name to BIMI Holdings Inc.;

4. On a non-binding advisory basis, the compensation of the Company’s executive officers;

5. On a non-binding advisory basis, annual  non-binding advisory votes on resolutions approving named executive officer compensation (“Say When on Pay Vote”); and

6. Ratified the appointment of Enrome LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2023.

About BIMI Holdings Inc.

BIMI Holdings Inc. is a healthcare products and services provider, offering a broad range of healthcare products and related services in the U.S. and Asia. For more information, please visit usbimi.com.

Investor Relations Contact
Investor Relations Department of BIMI International Medical Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +1 949 981 6274

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page